PL9643
Dry Eye Disease
Phase 3 CompletedInactive/Prioritized
Key Facts
Indication
Dry Eye Disease
Phase
Phase 3 Completed
Status
Inactive/Prioritized
Company
About Palatin Technologies
Palatin Technologies is a clinical-stage biopharmaceutical company leveraging its proprietary Melanocortin Receptor Platform to develop targeted therapeutics for inflammatory, autoimmune, and metabolic conditions. Its lead programs focus on MC4R agonists for obesity, particularly rare neuroendocrine disorders like hypothalamic obesity and Prader-Willi syndrome, representing a paradigm shift from broad immunosuppression to targeted resolution. Recent achievements include a strategic collaboration with Boehringer Ingelheim in retinal diseases and positive preclinical data for an oral obesity candidate, though the company operates as a pre-revenue entity navigating clinical development and financing risks.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Elate Ocular® | Cambium Bio | Phase 3 |
| OT-301 | Ocumension Therapeutics | Phase 2 |
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Care Portfolio | YD Bio | Commercial |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |
| MediPrint Lens (Dry Eye) | MediPrint Ophthalmics | Pre-clinical/Research |
| Tivanisiran | Sylentis | Phase 2/3 |
| A197 | Aramis Biosciences | Phase 2 |
| KM102 | Theratome Bio | Pre-clinical |
| iTEAR®100 Commercialization | Olympic Ophthalmics | Commercial |
| HydraD | EyeD Pharma | Pre-Clinical |
| ST-100 (Vezocolmitide) | Stuart Therapeutics | Phase 3 |